What are the indications, dosing regimen, contraindications, adverse effects, and counseling points for Airsupra (albuterol + budesonide) in adult patients with asthma?

Airsupra: Key Clinical Information

Airsupra is an FDA-approved fixed-dose combination inhaler containing albuterol 90 mcg and budesonide 80 mcg per actuation, indicated for as-needed treatment of bronchoconstriction and reduction of exacerbation risk in adults ≥18 years with asthma. 1

Indications

Airsupra is specifically approved for:

• As-needed treatment or prevention of bronchoconstriction in asthma
• Reducing the risk of severe asthma exacerbations
• Age restriction: Only approved for patients 18 years and older 1

This represents a paradigm shift from traditional SABA-only rescue therapy, as it addresses both acute bronchoconstriction and underlying airway inflammation simultaneously 2.

Dosing Regimen

Standard dose: 2 actuations (180 mcg albuterol/160 mcg budesonide total) as needed for asthma symptoms 1

Critical Dosing Parameters:

• Maximum: 6 doses (12 inhalations) per 24-hour period 1
• Use as needed for symptoms—this is NOT a maintenance therapy 2
• Can be used with or without concurrent maintenance ICS therapy 1

Priming Requirements:

• First use: Prime with 4 sprays into the air
• Re-prime with 2 sprays if: Not used for >7 days, dropped, or after cleaning 1
• Discard when dose counter reaches 0 1

Real-World Usage Patterns:

In the pivotal MANDALA trial, patients averaged 2.6-2.8 inhalations daily, with high daily use (≥8 inhalations/day) being rare. Patients maintained adherence to background maintenance therapy on ≥75% of days 3.

Contraindications

Absolute contraindication: Hypersensitivity to albuterol, budesonide, or any excipients 1

Warnings and Precautions

Deterioration of Asthma (Critical Warning)

If symptoms continue after using Airsupra or the patient requires more doses than usual, this signals asthma destabilization requiring immediate reevaluation of the entire treatment regimen 1.

Paradoxical Bronchospasm

Can occur, particularly with first use of a new canister. Discontinue immediately and institute alternative therapy if this occurs 1.

Cardiovascular Effects

• Use cautiously in patients sensitive to sympathomimetic drugs
• Monitor patients with cardiovascular disorders (can cause increased pulse rate, blood pressure) 1

Fatal Overdose Risk

Excessive use may be fatal—strictly adhere to maximum dosing limits 1.

Infection Considerations

Use with caution in patients with:

• Active or quiescent tuberculosis
• Fungal, bacterial, viral, or parasitic infections
• Ocular herpes simplex
• Chickenpox or measles can have more serious or fatal course in susceptible patients 1

Metabolic and Endocrine Effects

• Hypokalemia may occur 1
• Use cautiously in convulsive disorders, hyperthyroidism, diabetes mellitus, ketoacidosis 1
• Hypercorticism and adrenal suppression possible with very high dosages 1

Ophthalmologic Effects

• Glaucoma and cataracts may develop
• Consider ophthalmology referral if ocular symptoms develop 1

Oropharyngeal Candidiasis

Monitor periodically; advise patients to rinse mouth with water (without swallowing) after use if available 1.

Bone Mineral Density

Monitor patients with major risk factors for decreased bone mineral content 1.

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ritonavir): Use with caution—may cause systemic corticosteroid effects 1.

Other short-acting bronchodilators: Use judiciously with other short-acting beta-agonists 1.

Adverse Effects

Most common adverse reactions (≥1% incidence): 1

• Headache
• Oral candidiasis
• Cough
• Dysphonia

In clinical trials, adverse event frequencies were low and comparable between albuterol-budesonide and albuterol alone, regardless of daily usage patterns 3.

Clinical Efficacy Evidence

The approval was based on robust clinical trial data:

MANDALA trial (moderate-to-severe asthma): As-needed albuterol-budesonide 180/160 mcg reduced severe exacerbation risk by 26% compared to albuterol alone (HR 0.74; 95% CI 0.62-0.89; P=0.001) 4.

BATURA trial (mild asthma): In patients with uncontrolled mild asthma, albuterol-budesonide reduced severe exacerbation risk by 47% (HR 0.53; 95% CI 0.39-0.73; P<0.001) and decreased annualized exacerbation rate from 0.32 to 0.15 5.

Exercise-induced bronchoconstriction: Single dose 30 minutes pre-exercise provided 78.3% full protection versus 28.3% with placebo 6.

Key Counseling Points

For Patients:

1. This is rescue therapy, not maintenance therapy—use only as needed for symptoms
2. Never exceed 6 doses (12 puffs) in 24 hours
3. Rinse mouth after use to reduce oral candidiasis risk
4. If you need more puffs than usual or symptoms persist, contact your healthcare provider immediately
5. Prime before first use and re-prime if not used for >7 days
6. Watch the dose counter—discard when it reaches 0

For Clinicians:

1. This represents a paradigm shift: Airsupra addresses both bronchoconstriction and inflammation during symptom worsening, unlike SABA-only therapy 2
2. Aligns with 2020 NAEPP guidelines recommending concomitant ICS-SABA for mild persistent asthma in patients ≥12 years 7
3. Can be used across asthma severity spectrum (mild to moderate-to-severe) in adults
4. Not approved for children <18 years despite guideline support for the concept in adolescents ≥12 years 1
5. Monitor for increased rescue use as a marker of deteriorating asthma control
6. Systemic glucocorticoid exposure is reduced compared to traditional exacerbation management (mean 23.2 vs 61.9 mg/year) 5

Common Pitfall to Avoid:

Do not confuse this with single maintenance and reliever therapy (SMART)—Airsupra is not indicated for maintenance therapy and should not be used on a scheduled basis 2.